Posttransplant anemia: The role of sirolimus

Kidney International

Volumn 76, Issue 4, 2009, Pages 376-382

  Fishbane, Steven ^a   Cohen, David J ^b   Coyne, Daniel W ^c   Djamali, Arjang ^d   Singh, Ajay K ^e   Wish, Jay B ^f  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Anemia; MTOR; Posttransplant; Renal; Sirolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG DOSE ESCALATION; GRAFT FAILURE; HUMAN; KIDNEY TRANSPLANTATION; MICROCYTOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANEMIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 68249101040     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.231     Document Type: Review

References (57)

1. Yorgin PD, Belson A, Sanchez J et al. Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 2002; 40: 1306-1318.
2. Yorgin PD, Scandling JD, Belson A et al. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2002; 2: 429-435.
3. Mix TCH, Kazmi W, Khan S et al. Anemia: a continuing problem following kidney transplantation. Am J Transplant 2003; 3: 1426-1433.
4. Vanrenterghem Y, Ponticelli C, Morales JM et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3: 835-845.
5. Borrows R, Loucaidou M, Chusney G et al. Anaemia and congestive heart failure early post-renal transplantation. Nephrol Dial Transplant 2008; 23: 1728-1734.
6. Winkelmayer WC, Kewalramani R, Rutstein M et al. Pharmacoepidemiology of anemia in kidney transplant recipients. JAm Soc Nephrol 2004; 15: 1347-1352.
7. Karthikeyan V, Karpinski J, Nair RC et al. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2003; 4: 262-269.
8. Augustine JJ, Knauss TC, Schulak JA et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4: 2001-2006.
9. Besarab A, Caro J, Jarrell B et al. Effect of cyclosporine and delayed graft function on posttransplantation erythropoiesis. Transplantation 1985; 40: 624-631.
10. Reynolds JC, Agodoa LY, Yuan CM et al. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 1058-1068.
11. Schwimmer J, Nadasdy TA, Spitalnik PF et al. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41: 471-479.
12. Djamali A, Samaniego M, Muth B et al. Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol 2006; 1: 623-640.
13. Afzali B, Al-Khoury S, Shah N et al. Anemia after renal transplantation. Am J Kidney Dis 2006; 48: 519-536.
14. Pirsch JD, Becker BN. Another cause for the same old problem. Am J Transplant 2004; 4: 1931-1932.
15. Shah N, Al-Khoury S, Afzali B et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006; 81: 1112-1118.
16. Maheshwari A, Mishra R, Thuluvath PJ. Post-liver-transplant anemia: etiology and management. Liver Transpl 2004; 10: 165-173.
17. Imoagene-Oyedeji AE, Rosas SE, Doyle AM et al. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol 2006; 17: 3240-3247.
18. Rigatto C, Foley R, Jeffery J et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462-468.
19. Molnar MZ, Czira M, Ambrus C et al. Anemia is associated with mortality in kidney-transplanted patients - a prospective cohort study. Am J Transplant 2007; 7: 818-824.
20. Kamar N, Rostaing L. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008; 85: 1120-1124.
21. Winkelmayer WC, Lorenz M, Kramar R et al. Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. Am J Transplant 2004; 4: 2075-2081.
22. Winkelmayer WC, Chandraker A, Brookhart MA et al. A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant 2006; 21: 3559-3566.
23. Lorenz M, Winkelmayer WC, Hörl WH et al. Anaemia after renal transplantation. Eur J Clin Invest 2005; 35 (Suppl 3): 89-94.
24. Collins AJ, Li S, St PW et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol 2001; 12: 2465-2473.
25. Ma JZ, Ebben J, Xia H et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619.
26. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69: 560-564.
27. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
28. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
29. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int 2002; 61 (Suppl 80): S35-S38.
30. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
31. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
32. Kahan BD, Podbielski J, Napoli KL et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-1046.
33. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-1042.
34. Kreis H, Cisterne J-M, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260.
35. MacDonald AS for The RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
36. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522.
37. Kim M-J, Mayr M, Pechula M et al. Marked erythrocyte microcytosis under primary immunosuppression with sirolimus. Transpl Int 2006; 19: 12-18.
38. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
39. Pascual J. Everolimus in clinical practice - renal transplantation. Nephrol Dial Transplant 2006; 21 (Suppl 3): iii18-iii23.
40. Gonwa TA, Hricik DE, Brinker K et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-1567.
41. Friend P, Russ G, Oberbauer R et al. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int 2007; 20: 754-760.
42. Turkowski-Duhem A, Kamar N, Cointault O et al. Predictive factors of anemia within the first year post renal transplant. Transplantation 2005; 80: 903-909.
43. Thaunat O, Beaumont C, Chatenoud L et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005; 80: 1212-1219.
44. Maiorano A, Stallone G, Schena A et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 2006; 82: 908-912.
45. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-1875.
46. Russ G, Schena FP, Oberbauer R et al. Incidence and treatment of anemia after conversion to sirolimus vs continuation of calcineurin inhibitors in renal allograft recipients: 2-year results from the CONVERT trial. Presented at: American Society of Nephrology Renal Week 2006; November 14-19, 2006; San Diego, California. J Am Soc Nephrol 2006; 17: 18A.
47. Cahill BC, Somerville KT, Crompton JA et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22: 169-176.
48. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-3171.
49. Blázquez-Domingo M, Grech G, von LM. Translation initiation factor 4E inhibits differentiation of erythroid progenitors. Mol Cell Biol 2005; 25: 8496-8506.
50. Bouscary D, Pene F, Claessens Y-E et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003; 101: 3436-3443.
51. Jaster R, Bittorf T, Klinken SP et al. Inhibition of proliferation but not erythroid differentiation of J2E cells by rapamycin. Biochem Pharmacol 1996; 51: 1181-1185.
52. Mischiati C, Sereni A, Lampronti I et al. Rapamycin-mediated induction of γ-globin mRNA accumulation in human erythroid cells. Br J Haematol 2004; 126: 612-621.
53. KDOQI. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47 (Suppl 3): S11-S145.
54. KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530.
55. Lorenz M, Kletzmayr J, Perschl A et al. Anemia and iron deficiencies among long-term renal transplant recipients. J Am Soc Nephrol 2002; 13: 794-797.
56. Rigatto C. Anemia, renal transplantation, and the anemia paradox. Semin Nephrol 2006; 26: 307-312.
57. Turkowski-Duhem A, Kamar N, Cointault O et al. Predictive factors of postrenal transplant anemia. Transplant Proc 2005; 37: 1009-1011.